Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 130, Issue 10, Pages 5313-5325
Publisher
American Society for Clinical Investigation
Online
2020-07-01
DOI
10.1172/jci133310
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
- (2019) Rachael A. Vaubel et al. CLINICAL CANCER RESEARCH
- Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial
- (2018) Alan Mackay et al. CANCER CELL
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma
- (2018) Katherine Elizabeth Warren Frontiers in Oncology
- CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response
- (2018) Stefanie Stallard et al. Acta Neuropathologica Communications
- Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies
- (2017) Ranjeet Prasad Dash et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model
- (2016) R. K. Mittapalli et al. MOLECULAR CANCER THERAPEUTICS
- Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma
- (2016) Carl Koschmann et al. Oncotarget
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
- (2015) Andrew B. Lassman et al. NEURO-ONCOLOGY
- Platelet-Derived Growth Factor Receptor Alpha as a Marker of Mesenchymal Stem Cells in Development and Stem Cell Biology
- (2015) Ramin M. Farahani et al. Stem Cells International
- Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
- (2013) B. S. Paugh et al. CANCER RESEARCH
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- (2013) Y. Pignochino et al. CLINICAL CANCER RESEARCH
- Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence-Based Position
- (2013) J C Kalvass et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
- (2013) P. W. Lewis et al. SCIENCE
- Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors
- (2012) Mukul Minocha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib
- (2012) Mukul Minocha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- The disturbed blood–brain barrier in human glioblastoma
- (2012) Hartwig Wolburg et al. MOLECULAR ASPECTS OF MEDICINE
- Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents
- (2012) S. Agarwal et al. MOLECULAR CANCER THERAPEUTICS
- Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas
- (2012) A. Alentorn et al. NEURO-ONCOLOGY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Bevacizumab in recurrent high-grade pediatric gliomas
- (2010) A. Narayana et al. NEURO-ONCOLOGY
- Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
- (2009) J. S. Lagas et al. CLINICAL CANCER RESEARCH
- Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
- (2008) K. Porkka et al. BLOOD
- Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation
- (2008) B. Dewaele et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started